Mill Capital Management LLC Increases Holdings in Zoetis Inc. $ZTS

Mill Capital Management LLC increased its position in Zoetis Inc. (NYSE:ZTS) by 18.4% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 147,324 shares of the company’s stock after buying an additional 22,894 shares during the quarter. Zoetis accounts for 1.6% of Mill Capital Management LLC’s portfolio, making the stock its 18th largest position. Mill Capital Management LLC’s holdings in Zoetis were worth $21,556,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of ZTS. Vanguard Group Inc. lifted its holdings in shares of Zoetis by 0.8% in the 2nd quarter. Vanguard Group Inc. now owns 41,886,987 shares of the company’s stock worth $6,532,276,000 after acquiring an additional 330,823 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Zoetis by 0.9% during the 2nd quarter. Geode Capital Management LLC now owns 11,081,301 shares of the company’s stock valued at $1,721,356,000 after purchasing an additional 95,294 shares during the last quarter. Norges Bank purchased a new position in Zoetis in the 2nd quarter worth $809,491,000. Brown Advisory Inc. lifted its stake in Zoetis by 5.7% in the second quarter. Brown Advisory Inc. now owns 4,659,371 shares of the company’s stock worth $726,629,000 after purchasing an additional 250,829 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in Zoetis by 113.0% during the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 3,761,920 shares of the company’s stock valued at $586,671,000 after buying an additional 1,995,491 shares during the period. 92.80% of the stock is currently owned by institutional investors.

Zoetis Trading Down 1.3%

NYSE ZTS opened at $123.08 on Tuesday. The stock’s 50 day moving average is $123.31 and its 200 day moving average is $139.11. The company has a quick ratio of 2.28, a current ratio of 3.64 and a debt-to-equity ratio of 1.31. The firm has a market capitalization of $54.24 billion, a PE ratio of 20.68, a P/E/G ratio of 2.53 and a beta of 0.97. Zoetis Inc. has a twelve month low of $115.25 and a twelve month high of $177.40.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. Zoetis had a net margin of 28.21% and a return on equity of 57.19%. The firm had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.42 billion. During the same period in the prior year, the firm earned $1.58 EPS. The company’s revenue was up .5% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 3rd. Investors of record on Tuesday, January 20th will be paid a $0.53 dividend. This represents a $2.12 annualized dividend and a dividend yield of 1.7%. The ex-dividend date is Tuesday, January 20th. This is an increase from Zoetis’s previous quarterly dividend of $0.50. Zoetis’s dividend payout ratio (DPR) is currently 33.67%.

Analysts Set New Price Targets

A number of brokerages have commented on ZTS. Weiss Ratings raised Zoetis from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, January 13th. Morgan Stanley set a $160.00 price target on shares of Zoetis in a research report on Thursday, December 18th. The Goldman Sachs Group raised shares of Zoetis to a “buy” rating in a research note on Monday, December 15th. KeyCorp started coverage on Zoetis in a research note on Thursday, November 20th. They issued a “sector weight” rating on the stock. Finally, Barclays started coverage on Zoetis in a research report on Monday, December 8th. They set an “equal weight” rating and a $136.00 price target for the company. Six research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat, Zoetis currently has an average rating of “Hold” and an average price target of $160.18.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.